Pharmarise Holdings (TSE:2796) Debt-to-EBITDA : 23.37 (As of Feb. 2024)

Pharmarise Holdings Debt-to-EBITDA Chart

Pharmarise Holdings Annual Data
	Trend	May14	May15	May16	May17	May18	May19	May20	May21	May22	May23
Debt-to-EBITDA		Get a 7-Day Free Trial					6.53	5.29	4.08	3.68	3.93

Pharmarise Holdings Quarterly Data
	May19	Aug19	Nov19	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23	May23	Aug23	Nov23	Feb24
Debt-to-EBITDA	Get a 7-Day Free Trial															6.44	6.68	6.64	4.55	23.37

Competitive Comparison of Pharmarise Holdings's Debt-to-EBITDA

For the Pharmaceutical Retailers subindustry, Pharmarise Holdings's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Pharmarise Holdings's Debt-to-EBITDA Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Pharmarise Holdings's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Pharmarise Holdings's Debt-to-EBITDA falls into.

Pharmarise Holdings Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Pharmarise Holdings's Debt-to-EBITDA for the fiscal year that ended in May. 2023 is calculated as

Pharmarise Holdings's annualized Debt-to-EBITDA for the quarter that ended in Feb. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Feb. 2024) EBITDA data.

Pharmarise Holdings  (TSE:2796) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

Pharmarise Holdings Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Pharmarise Holdings's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

Pharmarise Holdings (TSE:2796) Business Description